Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

Inclusion Criteria:

• History of gout

• Occurrence of ≥ 2 self-reported gout flares in the last 12 months

• Body weight no less than 50 kg

• Patients who are NOT on approved urate-lowering therapy (ULT) must have sUA ≥ 7mg/dL

• Patients who are on medically appropriate ULT must have sUA > 6 mg/dL

• Serum creatinine must be < 3.0 mg/dL and estimated CLcr ≥ 30 mL/min

Exclusion Criteria:

• Malignancy within 5 years, except for successfully treated basal or squamous cellcarcinoma of the skin

• Pregnant or breastfeeding

• History of symptomatic kidney stones within the past 6 months